440356-89-8

Upstream product

• 24807-40-7 methyl 3-(4-benzyloxyphenyl)propanoate 
• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 
• 1073546-43-6 methyl 2-((4-((phenylmethyl)oxy)phenyl)methyl)butanoate 
• 251978-38-8 methyl 2-(4-hydroxybenzyl)butanoate 
• 440356-88-7 (R)-2-(4-Nitro-benzyl)-butyric acid methyl ester 
• 56640-46-1 (R)-2-(phenylmethyl)butyric acid 
• 138809-62-8 (R)-(-)-methyl 3-phenyl-2-ethylpropionate 

Downstream Products

• 440356-90-1 (R)-2-(4-Methoxy-benzyl)-butyric acid methyl ester 
• 440356-91-2 (R)-2-(3-Formyl-4-methoxy-benzyl)-butyric acid methyl ester 
• 440356-92-3 2-Methoxy-5-((R)-2-methoxycarbonyl-butyl)-benzoic acid 
• 440356-93-4 (R)-2-[4-Methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-butyric acid methyl ester 

Relevant academic research and scientific papers

SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula (I) where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha

Optically active phenylpropanoic acid derivatives [(S)-5, and (R)-5] were prepared, and their affinities for peroxisome proliferator-activated receptor (PPAR)α and PPARγ were evaluated. Binding assay and cell-based reporter assay indicated that the activi